This article is more than 5 years old. Information may no longer be current.

Visian ICL results in hyperopes promising at 1 year, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The STAAR Visian ICL is an effective and stable treatment for moderate to high hyperopia, according to 1-year follow-up in a clinical trial.

Paul Dougherty, MD, reported on the treatment of 243 eyes of 130 patients with hyperopia ranging from +1.6 D to +11.9 D (average +5.36 D) with the Visian ICL, formerly called the Implantable Contact Lens. Of the 156 eyes that completed 1-year follow-up, 46% achieved 20/20 or better uncorrected visual acuity, while 94% achieved 20/40 or better, according to Dr. Dougherty.

“The results are highly impressive for treating otherwise very difficult to treat patients with moderate to high hyperopia,” Dr. Dougherty said in a press release from Dougherty Laser Vision. “The [Visian] ICL is the first surgical technology that enables us to correct such high hyperopic patients without the unwanted side effect of surgically-induced presbyopia.”